Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BBNX NASDAQ:EMBC NYSE:INFU NASDAQ:TNDM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBNXBeta Bionics$20.20+0.5%$15.60$8.89▼$24.50$878.09MN/A558,901 shs539,151 shsEMBCEmbecta$14.96+3.2%$11.89$9.20▼$21.48$874.94M1.12631,380 shs618,453 shsINFUInfuSystem$10.16-4.4%$7.62$4.61▼$11.04$207.53M1.82177,809 shs225,946 shsTNDMTandem Diabetes Care$12.58+1.5%$14.07$9.98▼$47.60$850.02M1.452.19 million shs1.61 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBNXBeta Bionics0.00%+7.22%+33.86%+5.87%+2,019,999,900.00%EMBCEmbecta0.00%+3.31%+44.40%+52.81%-9.00%INFUInfuSystem0.00%-5.75%+35.11%+66.28%+65.20%TNDMTandem Diabetes Care0.00%+0.56%+9.20%-39.46%-69.41%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBNXBeta Bionics$20.20+0.5%$15.60$8.89▼$24.50$878.09MN/A558,901 shs539,151 shsEMBCEmbecta$14.96+3.2%$11.89$9.20▼$21.48$874.94M1.12631,380 shs618,453 shsINFUInfuSystem$10.16-4.4%$7.62$4.61▼$11.04$207.53M1.82177,809 shs225,946 shsTNDMTandem Diabetes Care$12.58+1.5%$14.07$9.98▼$47.60$850.02M1.452.19 million shs1.61 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBNXBeta Bionics0.00%+7.22%+33.86%+5.87%+2,019,999,900.00%EMBCEmbecta0.00%+3.31%+44.40%+52.81%-9.00%INFUInfuSystem0.00%-5.75%+35.11%+66.28%+65.20%TNDMTandem Diabetes Care0.00%+0.56%+9.20%-39.46%-69.41%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBBNXBeta Bionics 2.75Moderate Buy$22.5611.66% UpsideEMBCEmbecta 2.75Moderate Buy$19.0027.01% UpsideINFUInfuSystem 4.00Strong Buy$12.5023.03% UpsideTNDMTandem Diabetes Care 2.27Hold$22.4778.59% UpsideCurrent Analyst Ratings BreakdownLatest INFU, TNDM, EMBC, and BBNX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/26/2025EMBCEmbectaZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy8/21/2025TNDMTandem Diabetes CareCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$10.35 ➝ $11.008/11/2025TNDMTandem Diabetes CareLake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$75.00 ➝ $12.008/8/2025TNDMTandem Diabetes CareBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$53.00 ➝ $51.008/7/2025TNDMTandem Diabetes CareCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$59.00 ➝ $24.008/7/2025TNDMTandem Diabetes CarePiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Neutral$30.00 ➝ $14.008/7/2025TNDMTandem Diabetes CareUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$20.00 ➝ $17.008/7/2025TNDMTandem Diabetes CareWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$20.00 ➝ $13.008/7/2025TNDMTandem Diabetes CareRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$45.00 ➝ $25.007/30/2025BBNXBeta BionicsTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$18.00 ➝ $21.007/30/2025BBNXBeta BionicsRobert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetNeutral$15.00 ➝ $17.00(Data available from 9/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBBNXBeta Bionics$78.02M11.25N/AN/A($5.72) per share-3.53EMBCEmbecta$1.12B0.78$3.34 per share4.48($12.80) per share-1.17INFUInfuSystem$139.89M1.48$0.79 per share12.79$2.47 per share4.11TNDMTandem Diabetes Care$940.20M0.90N/AN/A$4.01 per share3.14Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBBNXBeta Bionics-$54.76MN/A0.00∞N/AN/AN/AN/AN/AEMBCEmbecta$78.30M$1.4310.464.870.837.58%-23.40%14.46%11/25/2025 (Estimated)INFUInfuSystem$870K$0.23169.3632.77N/A1.12%2.78%1.41%N/ATNDMTandem Diabetes Care-$96.03M-$3.09N/AN/AN/A-20.51%-65.40%-13.87%11/5/2025 (Estimated)Latest INFU, TNDM, EMBC, and BBNX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/8/2025Q3 2025EMBCEmbecta$0.7720$1.12+$0.3480$0.78$278.15 million$295.50 million8/6/2025Q2 2025TNDMTandem Diabetes Care-$0.40-$0.48-$0.08-$0.78$238.39 million$240.68 million7/29/2025Q2 2025BBNXBeta Bionics-$0.51-$0.39+$0.12-$0.39$19.73 million$23.24 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBBNXBeta BionicsN/AN/AN/AN/AN/AEMBCEmbecta$0.604.01%N/A41.96%N/AINFUInfuSystemN/AN/AN/AN/AN/ATNDMTandem Diabetes CareN/AN/AN/AN/AN/ALatest INFU, TNDM, EMBC, and BBNX DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date8/6/2025EMBCEmbectaquarterly$0.154.14%8/29/20258/29/20259/15/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBBNXBeta BionicsN/A14.6813.79EMBCEmbectaN/A2.471.78INFUInfuSystem0.501.981.59TNDMTandem Diabetes Care2.322.441.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBBNXBeta BionicsN/AEMBCEmbecta93.83%INFUInfuSystem71.13%TNDMTandem Diabetes CareN/AInsider OwnershipCompanyInsider OwnershipBBNXBeta BionicsN/AEMBCEmbecta0.42%INFUInfuSystem11.40%TNDMTandem Diabetes Care1.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBBNXBeta Bionics29443.47 millionN/AN/AEMBCEmbecta2,10058.49 million58.24 millionOptionableINFUInfuSystem41020.43 million19.10 millionOptionableTNDMTandem Diabetes Care2,65067.57 million66.29 millionOptionableINFU, TNDM, EMBC, and BBNX HeadlinesRecent News About These Companies252,600 Shares in Tandem Diabetes Care, Inc. $TNDM Acquired by Edmond DE Rothschild Holding S.A.5 hours ago | marketbeat.comTandem t:slim Mobile App Now Authorized by Health Canada for iPhone and Android PhonesSeptember 6 at 2:49 AM | theglobeandmail.com1 Volatile Stock with Exciting Potential and 2 We AvoidSeptember 4 at 7:08 PM | finance.yahoo.comFirst Light Asset Management LLC Lowers Stock Position in Tandem Diabetes Care, Inc. $TNDMSeptember 4 at 7:27 AM | marketbeat.comDAFNA Capital Management LLC Buys 71,000 Shares of Tandem Diabetes Care, Inc. $TNDMSeptember 1, 2025 | marketbeat.comKingdon Capital Management L.L.C. Lowers Holdings in Tandem Diabetes Care, Inc. $TNDMSeptember 1, 2025 | marketbeat.comCapital Fund Management S.A. Trims Stock Holdings in Tandem Diabetes Care, Inc. $TNDMAugust 29, 2025 | marketbeat.comTandem Diabetes Care, Inc. $TNDM Shares Acquired by HighTower Advisors LLCAugust 28, 2025 | marketbeat.comNuveen LLC Invests $5.91 Million in Tandem Diabetes Care, Inc. $TNDMAugust 28, 2025 | marketbeat.comRussell Investments Group Ltd. Has $2.67 Million Stake in Tandem Diabetes Care, Inc. $TNDMAugust 27, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Sells 32,171 Shares of Tandem Diabetes Care, Inc. $TNDMAugust 26, 2025 | marketbeat.comTandem Diabetes Care Inc News (TNDM) - Investing.comAugust 23, 2025 | investing.comTandem Diabetes Care, Inc. $TNDM Shares Purchased by Aberdeen Group plcAugust 23, 2025 | marketbeat.comVanguard Group Inc. Reduces Holdings in Tandem Diabetes Care, Inc. $TNDMAugust 23, 2025 | marketbeat.comTandem Diabetes Care (TNDM) Gets a Buy from RBC CapitalAugust 22, 2025 | theglobeandmail.comVersor Investments LP Buys Shares of 30,500 Tandem Diabetes Care, Inc. $TNDMAugust 22, 2025 | marketbeat.comAlgert Global LLC Purchases 119,784 Shares of Tandem Diabetes Care, Inc. $TNDMAugust 22, 2025 | marketbeat.comPublic Sector Pension Investment Board Raises Stock Position in Tandem Diabetes Care, Inc. $TNDMAugust 19, 2025 | marketbeat.comSector Gamma AS Acquires New Shares in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)August 17, 2025 | marketbeat.comTandem Diabetes Care, Inc. (NASDAQ:TNDM) Given Consensus Rating of "Hold" by BrokeragesAugust 15, 2025 | marketbeat.comTandem Diabetes Care, Inc. (TNDM) Investors Who Lost Money - Contact Law Offices of Howard G. Smith About Securities Fraud InvestigationAugust 14, 2025 | tmcnet.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025An Atomic Sized Surge Is Brewing for NuScale Power Stock PriceBy Thomas Hughes | August 11, 2025From Debt to Liftoff: EchoStar's $23 Billion CatalystBy Jeffrey Neal Johnson | August 27, 2025INFU, TNDM, EMBC, and BBNX Company DescriptionsBeta Bionics NASDAQ:BBNX$20.20 +0.10 (+0.50%) As of 09/5/2025 04:00 PM EasternBeta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.Embecta NASDAQ:EMBC$14.96 +0.47 (+3.24%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$14.97 +0.01 (+0.07%) As of 09/5/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.InfuSystem NYSE:INFU$10.16 -0.47 (-4.42%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$10.34 +0.18 (+1.72%) As of 09/5/2025 06:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.Tandem Diabetes Care NASDAQ:TNDM$12.58 +0.19 (+1.53%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$12.72 +0.14 (+1.11%) As of 09/5/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Union Pacific: Laying the Tracks for America's Industrial Renewal TransDigm’s Edge: From Spare Parts to Sky-High Profits Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
